REVIEW

Circulation Journal Official Journal of the Japanese Circulation Society http://www. j-circ.or.jp

Unveiling Specific Triggers and Precipitating Factors for Fatal Cardiac Events in Inherited Arrhythmia Syndromes Tadashi Nakajima, MD; Yoshiaki Kaneko, MD; Masahiko Kurabayashi, MD

Patients with inherited arrhythmia syndromes, such as long QT syndrome, Brugada syndrome, early repolarization syndrome, catecholaminergic polymorphic ventricular tachycardia, and their latent forms, are at risk for fatal arrhythmias. These diseases are typically associated with genetic mutations that perturb cardiac ionic currents. The analysis of cardiac events by genotype-phenotype correlation studies has revealed that fatal arrhythmias in some genotypes are triggered by physical or emotional stress, and those in the others are more likely to occur during sleep or at rest. Thus, the risk stratification and management of affected patients differ strikingly according to the genetic variant of the inherited arrhythmia syndrome. Risk stratification may be further refined by considering the precipitating factors, such as drugs, bradycardia, electrolyte disturbances, fever, and cardiac memory. Moreover, an increasing number of studies imply that the susceptibility of fatal arrhythmias in patients with acute coronary syndrome or takotsubo cardiomyopathy is at least partly ascribed to the genetic variants causing inherited arrhythmia syndromes. In this article, we review the recent advances in the understanding of the molecular genetics and genotype-phenotype correlations in inherited arrhythmia syndromes and consider the triggers and precipitating factors for fatal arrhythmias in these disorders. Further studies to explore the triggers and precipitating factors specific to the genotypes and diseases are needed for better clinical management.   (Circ J 2015; 79: 1185 – 1192) Key Words: Fatal arrhythmias; Genes; Mutations; Precipitating factors; Triggers

S

ince the identification of the genes for long QT syndrome (LQTS) manifesting as syncope and sudden cardiac death (SCD), an increasing number of new genes associated with a new group of syndrome, called the inherited arrhythmia syndromes, have been discovered. Those include LQTS, Brugada syndrome (BrS), early repolarization syndrome (ERS) and catecholaminergic polymorphic ventricular tachycardia (CPVT) etc, and the term “channelopathies” defines the inherited arrhythmia syndromes caused by mutations of the genes encoding cardiac ion channel proteins or their modifiers that regulate cardiac ion channels. Patients with an inherited arrhythmia syndrome are at variable risk for SCD and need to be managed according to risk stratification that includes the genotype of the disease. Current pharmacological treatments are not always successful in preventing cardiac events and an implantable cardioverter defibrillator (ICD) is the only option for high-risk patients; therefore, risk stratification is a critical step in clinical management. In particular, the identification of triggers and precipitating factors for fatal arrhythmias is effective for predicting cardiac events and reducing the risk for SCD. This review will focus on the genetic basis and the triggers or precipitating factors for fatal arrhythmias in inherited arrhythmia syndromes, including their latent forms. Recent studies points to an important role for genetic variants of ion channels

in patients with acute coronary syndrome (ACS) or takotsubo cardiomyopathy accompanying fatal arrhythmias.

Inherited Arrhythmia Syndromes LQTS LQTS is a genetically heterogeneous disorder characterized by QT interval prolongation on ECG and polymorphic VT, torsades de pointes (TdP), leading to syncope and SCD. Since the discovery of 3 causative genes (KCNQ1 for LQT1; KCNH2 for LQT2; SCN5A for LQT3) in 1995 and 1996,1–3 to date at least 13 genes for LQTS have been identified (Table 1).4–6 Most of them encode cardiac ion channels or their modifiers. The first 3 LQTS (LQT1–3) account for approximately 75% of clinically definite LQTS, and the other genes account for only 5% of cases. KCNQ1 and KCNH2 encode the α-subunit of the slow component (IKs) and rapid components (IKr), respectively, of the delayed rectifier potassium currents.7,8 SCN5A encodes the α-subunit of the cardiac voltage-gated sodium channels (sodium currents: INa).3 A decrease of the outward currents (IKs, IKr) or an increase of the inward currents (INa) in ventricular myocytes causes a delay of repolarization, thus leading to prolongation of the QT interval on ECG (Figure 1). TdP is thought to be triggered by ventricular action potential (AP) phase 2

Received March 22, 2015; accepted April 8, 2015; released online April 30, 2015 Department of Medicine and Biological Science, Gunma University Graduate School of Medicine, Maebashi, Japan Mailing address:  Tadashi Nakajima, MD, PhD, Department of Medicine and Biological Science, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi 371-8511, Japan.   E-mail: [email protected] ISSN-1346-9843  doi: 10.1253/circj.CJ-15-0322 All rights are reserved to the Japanese Circulation Society. For permissions, please e-mail: [email protected] Circulation Journal  Vol.79, June 2015

1186

NAKAJIMA T et al.

Table 1.  Responsible Genes and Their Altered Functions in Inherited Arrhythmia Syndromes Gene

Protein

Function

LQTS   LQT1

KCNQ1

Kv7.1

↓ IKs

  LQT2

KCNH2

Kv11.1

↓ IKr

  LQT3

SCN5A

Nav1.5

↑ INa

  LQT4

ANKB

Ankyrin

↓ Na/K, ATPase

  LQT5

KCNE1

MinK

↓ IKs

  LQT6

KCNE2

MiRP1

↓ IKr

  LQT7

KCNJ2

Kir2.1

↓ IK1

  LQT8

CACNA1C

Cav1.2

↑ ICa

  LQT9

CAV3

Caveolin-3

↑ INa

  LQT10

SCN4B

Navβ4

↑ INa

  LQT11

AKAP9

Yotiao

↓ IKs

  LQT12

SNTA1

Syntrophin-α1

↑ INa

  LQT13

KCNJ5

Kir3.4

  LQT

CALM1

Calmodulin

↓ Ca2+ binding to proteins

  LQT

CALM2

Calmodulin

↓ Ca2+ binding to proteins

↓ IK-Ach

BrS   BrS1

SCN5A

Nav1.5

↓ INa

  BrS2

GPD1-L

GPD1-L

↓ INa

  BrS3

CACNA1C

Cav1.2

↓ ICa

  BrS4

CACNB2b

Cavβ2b

↓ ICa

  BrS5

SCN1B

Navβ1

↓ INa

  BrS6

KCNE3

MiRP2

↑ Ito

  BrS7

SCN3B

Navβ3

↓ INa

  BrS8

KCNJ8

Kir6.1

↑ IK-ATP

  BrS9

CACNA2D1

Cavα2d

↓ ICa

  BrS10

KCND3

Kv4.3

↑ Ito

  BrS11

MOG1

MOG1

↓ INa

  BrS12

ABCC9

SUR2A

↑ IK-ATP

ERS   ERS1

KCNJ8

Kir6.1

↑ IK-ATP

  ERS2

CACNA1C

Cav1.2

↓ ICa

  ERS3

CACNB2b

Cavβ2b

↓ ICa

  ERS4

CACNA2D1

Cavα2d

↓ ICa

  ERS5

ABCC9

SUR2A

↑ IK-ATP

  ERS6

SCN5A

Nav1.5

↓ INa

  CPVT1

RYR2

Ryanodine receptor

  CPVT2

CASQ2

CPVT ↑ Ca2+ release from SR

Calsequestrin-2 ↑ Ca2+ release from SR ↓ IK1

  CPVT3

KCNJ2

Kir2.1

  CPVT4

TRDN

Triadine

  CPVT5

CALM1

Calmodulin

↓ Ca2+ binding to proteins

  CPVT6

CALM2

Calmodulin

↓ Ca2+ binding to proteins

Modified with permission from Mizusawa Y, et al6 and Antzelevitch C.20 BrS, Brugada syndrome; CPVT, catecholaminergic polymorphic ventricular tachycardia; ERS, early repolarization syndrome; LQTS, long QT syndrome; SR, sarcoplasmic reticulum.

early afterdepolarization under conditions of a prolonged QT interval.4 Because the IKs activates very slowly on depolarization and is increased by sympathetic activation, its net repolarizing current can accumulate at higher heart rates, thus

Figure 1.   Mechanisms of prolongation of repolarization and QT interval, and contributed ionic currents associated with major types of long QT syndrome (LQT1–3). (A) Schematic representation of the ventricular action potential, (B) surface ECG lead, and (C) ionic currents. Loss-of-function of IKs and IKr, or gain-of-function of INa can theoretically cause prolongation of repolarization and the QT interval (red lines). The dotted red line in (A) indicates early afterdepolarization.

contributing to QT adaptation during tachycardia. Loss-offunction of the IKs by KCNQ1 mutations can theoretically cause QT prolongation, especially during tachycardia. Indeed, cardiac events in LQT1 mostly occur during physical exertion or emotional stress, typically during swimming (Table 2).9 The IKr rapidly activates but is suppressed by strong depolarization because of its inward rectification property.8 Emotional stress and sudden auditory stimuli are major triggers for cardiac events in LQT2 (Table 2).9,10 Moreover, female patients with LQT2 have an increased risk of cardiac events during the postpartum period.11 In contrast to LQT1 and LQT2, cardiac events in LQT3 patients mainly occur during sleep or at rest (Table 2).9 In this manner, the triggers for fatal arrhythmias in LQTS differ strikingly among the genotypes. β-blocker therapy (propranolol or nadolol but not metoprolol) is extremely effective for patients with LQT1,12,13 and also partly effective in patients with LQT2,13 but efficacy is controversial in patients with LQT3.14 Mexiletine, which blocks persistent INa, can shorten the QT interval and may be effective in LQT3.15 The appropriate guidance to avoid specific triggers for fatal arrhythmias should be given to genotyped LQTS

Circulation Journal  Vol.79, June 2015

Precipitating Factors for Fatal Arrhythmias

1187

Table 2.  Typical Triggers for Fatal Arrhythmias and Appropriate Medical Therapy in Inherited Arrhythmia Syndromes Typical trigger

Medical therapy

LQT1

Exercise, swimming

β-blockers

LQT2

Emotion, auditory stimuli, postpartum period

β-blockers, potassium supplement

LQT3

Sleep, rest

(β-blockers), mexiletine

BrS

Sleep, rest, fever

Isoproterenol infusion, quinidine, bepridil, cilostazol

ERS

Sleep, rest

Isoproterenol infusion, quinidine, bepridil, cilostazol

Exercise

β-blockers, flecainide

CPVT Abbreviations as in Table 1.

patients. In LQT1, excessive physical stress, especially swimming, should be avoided. In LQT2, the use of items that cause sudden noises such as alarm clocks and ringing telephones should be avoided. LQTS patients who experience aborted cardiac arrest or are resistant to optimal medical therapy are indicated for ICD. Left cardiac sympathetic denervation (LCSD) is another therapeutic option for patients at high risk.16 BrS BrS is a hereditable disorder characterized by ST segment elevations in the right precordial ECG leads, associated with a high incidence of syncope or SCD because of fatal arrhythmias, which mostly affects adult males.4,17 The transient outward potassium current (Ito), which is abundant in the right ventricular epicardium compared with the endomyocardium, has been postulated to contribute to the pathogenesis of BrS. The presence of a prominent Ito-mediated AP notch in the right ventricular epicardium but not endomyocardium causes a transmural voltage gradient manifested as a J-point elevation on the right precordial ECG leads.18 An additional decrease of the inward currents (INa, ICa: Ca currents) or increase of the outward currents (Ito and IK-ATP: ATP-sensitive potassium channels) during the early phase of the AP can theoretically lead to an increased transmural voltage gradient, manifesting as the Brugada ECG pattern and phase 2 reentry.18 Since the first identification of a causative SCN5A mutation in 1998,19 BrS has been linked to mutations in genes that perturb cardiac ionic currents contributing to the early phase of the AP (Table 1).4,5,20,21 Mutations in SCN5A that cause loss-of-function of the INa have accounted for the major form of BrS in approximately 20% of cases, and other gene mutations account for approximately 10%; thus, approximately 70% of BrS cases remain to be genetically elucidated. In contrast to LQTS, the knowledge about the genotypephenotype correlation in BrS is limited. Cardiac events in BrS patients mostly occur during sleep or at rest (Table 2).22 ICD is the only available treatment for preventing SCD. Isoproterenol infusion, which increases the ICa and suppresses the Ito by insufficient recovery from inactivation with increasing heart rate, is useful for suppressing the electrical storm of ventricular fibrillation (VF).22 Quinidine and bepridil, which have an inhibitory effect on Ito, and cilostazol, a phosphodiesterase III inhibitor that increases ICa through elevation of cAMP, have been shown to be effective to some extent as adjunctive therapy in cases of frequent ICD shocks (Table 2).23–25 ERS The ER or J wave is characterized by ≥0.1 mV J-point elevation in 2 contiguous inferior and/or lateral ECG leads. The prevalence of ER in the general population is highly variable

and ranges from 1% to 13%.26 An ER pattern was long thought to be a benign ECG manifestation. However, Haissaguerre et al demonstrated an association between ER and idiopathic VF in 2008,27 and the combination is now defined as ERS.20 As with BrS, a higher epicardial Ito relative to the endocardium, as well as other ionic currents contributing to the early phase of the AP, have been implicated as important mediators of ER. ERS shares similar ECG characteristics, clinical characteristics and risk factors with BrS.20 Most patients with ERS experience arrhythmic events during sleep or at rest (Table 2). Of note, the genetic basis for ERS overlaps that for BrS (Table 1).20 The presence of ER on ECG is associated with electrical storm in patients with BrS.28 Akin to BrS, VF can be suppressed to some extent by quinidine, bepridil, cilostazol, and isoproterenol infusion or with pacing at increasingly rapid rates (Table 2).25,29,30 CPVT CPVT is a hereditable disorder characterized by adrenergicinduced bidirectional and polymorphic VT without structural heart diseases, leading to syncope and SCD.31,32 RYR2 (encoding the cardiac ryanodine receptor), CAQS2 (encoding cardiac calsequestrin), KCNJ2 (encoding IK1: inwardly rectifying potassium currents), TRDN (encoding the junctional protein triadine) have been identified as causative genes for CPVT (Table 1).5,32,33 Recently, mutations in 2 (CALM1 and CALM2) of 3 genes (CALM1–3) encoding identical peptide sequences for the essential Ca2+-signaling protein calmodulin were reported to be associated with malignant forms of LQTS, CPVT and idiopathic VF.34,35 In CPVT, cytosolic Ca2+ overload in ventricular myocytes or Purkinje cells generates inward currents thorough the Na+/ Ca2+ exchanger, leading to membrane depolarization called delayed afterdepolarization (DAD). If Ca2+ overload under adrenergic conditions is sufficient to bring DAD to a threshold, it induces full AP, manifesting as ventricular ectopies on ECG.32 Exercise or catecholamine infusion can easily induce an arrhythmic burden in patients with CPVT.31,36 Therefore, exercise should be limited in affected patients. β-blocker therapy can reduce the arrhythmia burden and death, so is the first choice for CPVT, but is not completely effective.31 Patients with CPVT resistant to β-blocker therapy should be considered for flecainide (Table 2).37 Combined therapy with LCSD can be also considered. ICD should be the last intervention because the device can potentially have proarrhythmic effects because discharges could prove disastrous by evoking a selfinduced vicious circle.32

Circulation Journal  Vol.79, June 2015

1188

NAKAJIMA T et al.

Table 3.  Precipitating Factors for Fatal Arrhythmias Associated With Inherited Arrhythmia Syndromes and Their Latent Forms Precipitating factor

Phase

Fatal arrhythmia

Phenotype

Responsible gene and mutation/variant

TdP

LQTS

LQTS-causing genes (≤40%)

VF

BrS

Bradyarrhythmias

TdP

LQTS

LQTS-causing genes (17–28%); common in KCNH2 but rare in KCNQ1

Hypokalemia

TdP

LQTS

LQTS-causing genes

Fever

VF

BrS

SCN5A

TdP

LQTS

KCNH2 (S5-pore region)

LQTS

KCNH2 R744X, SCN5A E446K, KCNH2 K897T, KCNQ1 G643S

Drugs

ACS

Takotsubo cardiomyopathy

Acute

Electrical storm

Subacute

TdP

SCN5A G400A

Acute

VF

Subacute

TdP

LQTS

KCNH2 V115-A121dup

TdP

LQTS

KCNH2

Cardiac memory

ACS, acute coronary syndrome; TdP, torsades de pointes; VF, ventricular fibrillation. Other abbreviations as in Table 1.

Precipitating Factors for Fatal Arrhythmias Several factors are known to be precipitators for cardiac events in patients with inherited arrhythmia syndromes or their latent forms (Table 3). Combinations of precipitating factors can increase the risk of fatal arrhythmias. Gene-specific or mutation site-specific precipitating factors may also be present. Drugs Not only QT-prolonging antiarrhythmic drugs, such as quinidine and sotalol, but also other non-antiarrhythmic drugs, such as antihistamines, antibiotics and antipsychotics, exhibit marked QT prolongation and development of TdP (drug-induced LQTS (dLQTS)).38 (refer to www.qtdrugs.org). QT prolongation is mainly caused by the IKr-blocking effect of the culprit drug. After a washout period, the QT interval usually returns to within the normal range in patients with dLQTS. Mutations or variants in the LQTS-causing genes, including KCNQ1, KCNH2, KCNE1, KCNE2 and SCN5A, have been identified in up to 40% of patients with dLQTS (Table 3).39–43 Of note, functional analysis revealed that KCNQ1 or KCNH2 mutations identified in dLQTS showed no dominant-negative suppression or only a relatively mild decreased current density compared with those identified in congenital LQTS (cLQTS).42 Drugs that have an IKr-blocking effect lead to further reductions of the repolarizing currents in patients with a latent genetic background of mildly reduced repolarizing currents, thus unmasking dLQTS. Interestingly, colleagues have reported that K+ channel regulator-1 (KCR1), homologous to yeast α-1,2-glucosyltransferase ALG10, protects KCNH2 currents from pharmacological block by QT-prolonging antiarrhythmic drugs through enhancing of cellular glycosylation by acting as an α-1,2-glucosyltransferase.44,45 They demonstrated that the common variant KCR1 I447V, less common in patients with dLQTS than in control subjects, reduced the drug sensitivity of KCNH2 to dofetilide, whereas the KCR1 E33D variant identified in a patient with VF and significant QT prolongation increased it through reduced α-1,2-glucosyltransferase activity.44,46 Common variants of NOS1AP have been reported to be associated with a significant increase in the risk of dLQTS.47 Also, common variants in drug metabolism pathways may also predispose to dLQTS in a drug-specific fashion. In the case of dLQTS, QT-prolonging drugs and those interfering with their metabolism must be promptly discontin-

ued. Intravenous magnesium sulfate is the initial therapy of choice regardless of serum level. Serum potassium, which paradoxically increases the IKr, should be maintained in the highnormal range. Because drug-induced TdP is pause-dependent, as with other acquired LQTS, temporal cardiac pacing is highly effective in preventing recurrence of TdP. If temporal cardiac pacing is not available or while preparing for it, isoproterenol infusion should be considered to increase heart rate. On the other hand, many drugs, including antiarrhythmic drugs, psychotropic drugs, and anesthetic drugs, have been reported to induce the Brugada ECG and/or fatal arrhythmias in patients with BrS (refer to www.brugadadrugs.org).48 Patients with BrS should be advised not to use these drugs or to use them only under controlled conditions. Bradyarrhythmias Between 5% and 30% of patients with complete atrioventricular block (AVB) develop TdP.49 Patients with AVB-induced TdP display an abnormally prolonged QT interval at slower heart rates than do those without TdP, though, in general, the slower the heart rate, the longer repolarization.38 KCNQ1, KCNH2, KCNE2 and SCN5A mutations have been reported in approximately 17–28% patients with bradycardiainduced LQTS (Table 3).49–51 Of note, the KCNH2 mutation has been the most common, but KCNQ mutation is quite rare compared with cLQTS. Only a single KCNQ1 mutation, G272V, had been reported to date.51 The functional consequences of KCNQ1 and KCNH2 mutations are loss-of-function of each current (IKs, IKr), with milder suppression than in cLQTS.49,51 Electrolyte Disturbances Electrolyte disturbances such as hypokalemia, hypocalcemia and hypomagnesemia, especially hypokalemia, are major precipitating factors for TdP.38 Hypokalemia-induced LQTS can be present in all LQTS genotypes (Table 3). Hypokalemia is thought to decrease KCNH2/IKr currents because of enhanced channel block by Na+ and enhanced voltage-dependence of KCNH2 channel inactivation,52,53 and increased internalization and degradation of KCNH2 channels in the plasma membrane, thus prolonging the QT interval.54 Conversely, elevated serum potassium within the normal-high range by long-term oral potassium administration results in improvement in repolarization in patients with LQT2, and is thus considered as adjunctive therapy in LQT2 (Table 2).55

Circulation Journal  Vol.79, June 2015

Precipitating Factors for Fatal Arrhythmias

1189

Figure 2.   Fever-induced coved-type ST elevations and frequent premature ventricular contractions in a patient with Brugada syndrome. 12-lead ECG recorded at (A) normal body temperature (36.2°C) and (B) in a febrile state (38.5°C).

Figure 3.  Location of KCNH2 mutations associated with fever-induced long QT syndrome in a predicted topology of KCNH2. Red filled circles indicate the mutation sites.

Fever Fever has been reported as a precipitating factor for fatal arrhythmias in both BrS and LQTS (Table 3). In some BrS patients, fever unmasks the Brugada ECG and also triggers fatal arrhythmias.56 A representative case is shown in Figure 2. Cellular electrophysiological studies using a patch-clamp method have demonstrated that SCN5A mutations (eg, V1340I, F1344S, D1714G) impair cardiac sodium channel gating more severely at higher temperatures, leading to further INa reduction during fever.57–59 Thus, pronounced reduction of INa during fever is thought to increase arrhythmogenicity in BrS patients. Concerning LQTS, although the QT interval in healthy people is usually shortened during fever, A558P, T613M and F640V mutations of KCNH2 have been reported as associated with prolongation of the QT interval and development of TdP

during fever.60,61 We also recently identified a G584S mutation in KCNH2, which has been previously identified in patients with mild phenotype,62 in a female patient with dLQTS who developed TdP during fever.63 Of note, these mutations converge at the S5-Pore region in KCNH2 (Figure 3), a region that has been postulated to be related to voltage-dependent inactivation of KCNH2 channels.64,65 Functional analysis has demonstrated that wild-type (WT) KCNH2 increased current amplitudes when temperature is elevated, but mutants (A558P, F640V) did not much increase current amplitudes compared with the WT, possibly because of its faster inactivation rate at elevated temperature, which suggested that the failure of an increase of IKr might be the cause of QT prolongation and TdP during fever.60 These findings make us aware of the importance of reducing body temperature by timely use of antipyretics.

Circulation Journal  Vol.79, June 2015

1190

NAKAJIMA T et al.

ACS ACS is often accompanied by the development of fatal arrhythmias during its acute phase. Despite successful resuscitation from aborted SCD, fatal arrhythmias sometimes occur incessantly, the so-called electrical storm. A novel SCN5A G400A mutation has been identified in a patient who experienced electrical storm during the acute phase of myocardial infarction (MI) (Table 3).66 Myocardial ischemia and subsequent reperfusion result in increased production of reactive oxygen species (ROS), which induced a wide range of modifications to cellular lipids, nucleic acids and proteins, and the cardiac sodium channel is 1 of the proteins that can be modified by ROS.67 Besides reduction of INa by SCN5A mutation, further reduction of the INa in the setting of ACS may cause pronounced slowed conduction and prolonged refractoriness in the ventricular myocardium, leading to the formation of a substrate for reentry. Therefore, indigenous INa reduction may contribute to electrical storm during the acute phase of ACS. On the other hand, a rare form of fatal arrhythmia, which is associated with excessive QT prolongation and has the characteristics of pause-dependent TdP (ACS-TdP), was reported to occur during the subacute phase of ACS (3–11 days after presentation) in 8 (1.8%) of 434 patients.68 Crotti et al reported that 2 (15%) of 13 Caucasian patients with ACS-TdP were found to carry LQTS mutations (KCNH2 R744X, SCN5A E446K) (Table 3).69 Additionally, 9 (82%) of the remaining 11 patients carried the KCNH2 K897T variant, which is commonly present in an allele frequency of 35% in Caucasians but is rare in Asians. We have previously reported a patient with ACS-TdP, in whom we identified a KCNQ1 G643S variant.70 Carriers of the variant are at higher risk for fatal arrhythmias in the presence of appropriate precipitating factors such as bradycardia and hypokalemia, and the variant shows mild reduction of the KCNQ1/KCNE1 (IKs) channels,71 although the allele frequency of the variant in Asians is approximately 6–10%.72 A rat experimental model of MI showed that downregulation of potassium channel gene expression (ERG, KCNE1, KCNQ1) and the potassium currents (IKr, IKs) occurs in surviving myocytes from the infarct zone 2 days after MI.73 This suggests that major repolarizing currents (ie, IKr and IKs) may be reduced in the actual setting of the subacute phase of ACS in humans. Therefore, it is conceivable that patients with genetic variants, such as KCNQ1 G643S and KCNH2 K897T, would be at higher risk of TdP in the presence of additional reduction of repolarizing currents during the subacute phase of ACS. Takotsubo Cardiomyopathy Takotsubo cardiomyopathy is characterized by transient ventricular dysfunction in the absence of coronary artery disease and accompanied by repolarization abnormalities, including T-wave inversions and QT prolongation. It is commonly triggered by severe emotional or physical stress.74 The exact underlying mechanisms of the disease remain unclear; however, it is believed that ventricular dysfunction and subsequent repolarization abnormalities result from catecholamine-mediated myocardial toxicity. Madias et al reported that 8 (8.6%) of 93 total patients with takotsubo cardiomyopathy developed TdP or VF.75 The QT interval became pronouncedly prolonged over the 24–48 h after presentation, and most cases of TdP or VF occurred during the subacute phase of the disease. The initiation pattern of TdP exhibits characteristics of pause-dependent LQTS. A novel duplication mutation (V115-A121dup) in the Per-Arnt-Sim domain of KCNH2 has been identified in a patient with

takotsubo cardiomyopathy who experienced excessive QT prolongation and syncope (Table 3),76 suggesting that patients with LQTS have a higher risk of TdP when experiencing takotsubo cardiomyopathy. Cardiac Memory Cardiac memory is characterized by an altered T wave (marked inversion of T-wave polarity with QT prolongation) on the surface ECG during normal ventricular activation following altered electrical activation such as left bundle branch block, ventricular preexcitation and right ventricular pacing.77 Although cardiac memory is usually considered benign, cessation of long-lasting ventricular pacing has induced T-wave polarity changes with marked QT prolongation after a normal ventricular activation pattern, followed by TdP in a LQT2 patient (Table 3).78 Therefore, apart from patients with pause-dependent TdP, unnecessary ventricular pacing should be avoided in LQTS patients. Conversely, in LQTS patients with ventricular pacing, the appearance of occasional spontaneous normal rhythm should be inhibited. Besides those mentioned, other factors such as congestive heart failure, nervous system injury, starvation, female sex etc are also known as precipitating factors for fatal arrhythmias.38

Conclusions In this review, we have highlighted the triggers and precipitating factors for fatal arrhythmias in patients with inherited arrhythmia syndromes, including their latent forms, in which clinical phenotypes become manifest under specific conditions (drugs, bradycardia, electrolyte disturbances, fever, ACS, takotsubo cardiomyopathy, and cardiac memory). At present, risk stratification is based on clinical phenotype, including episodes of syncope, findings of the surface ECG and electrophysiological study, and family history for SCD, and the yield of genetic testing is not sufficient to determine the risk for future events. Further studies to unmask the potential triggers and precipitating factors for fatal cardiac events in patients carrying genetic variants associated with inherited arrhythmia syndromes is urgently required to improve the risk stratification process. Acknowledgments This work was supported by JSPS KAKENHI Grant Number 26461056.

Disclosures None.

References  1. Wang Q, Curran ME, Splawski I, Burn TC, Millholland JM, VanRaay TJ, et al. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet 1996; 12: 17 – 23.  2. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995; 80: 795 – 803.   3. Wang Q, Shen J, Splawski I, Atkinson D, Li Z, Robinson JL, et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 1995; 80: 805 – 811.   4. Shimizu W. Update of diagnosis and management of inherited cardiac arrhythmias. Circ J 2013; 77: 2867 – 2872.   5. Schwartz PJ, Ackerman MJ, George AL Jr, Wilde AA. Impact of genetics on the clinical management of channelopathies. J Am Coll Cardiol 2013; 62: 169 – 180.   6. Mizusawa Y, Horie M, Wilde AA. Genetic and clinical advances in congenital long QT syndrome. Circ J 2014; 78: 2827 – 2833.   7. Sanguinetti MC, Curran ME, Zou A, Shen J, Spector PS, Atkinson DL, et al. Coassembly of K(V)LQT1 and minK (IsK) proteins to form

Circulation Journal  Vol.79, June 2015

Precipitating Factors for Fatal Arrhythmias cardiac I(Ks) potassium channel. Nature 1996; 384: 80 – 83.   8. Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995; 81: 299 – 307.  9. Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, et al. Genotype-phenotype correlation in the long-QT syndrome: Gene-specific triggers for life-threatening arrhythmias. Circulation 2001; 103: 89 – 95. 10. Wilde AA, Jongbloed RJ, Doevendans PA, Duren DR, Hauer RN, van Langen IM, et al. Auditory stimuli as a trigger for arrhythmic events differentiate HERG-related (LQTS2) patients from KVLQT1related patients (LQTS1). J Am Coll Cardiol 1999; 33: 327 – 332. 11. Seth R, Moss AJ, McNitt S, Zareba W, Andrews ML, Qi M, et al. Long QT syndrome and pregnancy. J Am Coll Cardiol 2007; 49: 1092 – 1098. 12. Vincent GM, Schwartz PJ, Denjoy I, Swan H, Bithell C, Spazzolini C, et al. High efficacy of β-blockers in long-QT syndrome type 1: Contribution of noncompliance and QT-prolonging drugs to the occurrence of β-blocker treatment “failures”. Circulation 2009; 119: 215 – 221. 13. Abu-Zeitone A, Peterson DR, Polonsky B, McNitt S, Moss AJ. Efficacy of different beta-blockers in the treatment of long QT syndrome. J Am Coll Cardiol 2014; 64: 1352 – 1358. 14. Calvillo L, Spazzolini C, Vullo E, Insolia R, Crotti L, Schwartz PJ. Propranolol prevents life-threatening arrhythmias in LQT3 transgenic mice: Implications for the clinical management of LQT3 patients. Heart Rhythm 2014; 11: 126 – 132. 15. Ruan Y, Liu N, Bloise R, Napolitano C, Priori SG. Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients. Circulation 2007; 116: 1137 – 1144. 16. Bos JM, Bos KM, Johnson JN, Moir C, Ackerman MJ. Left cardiac sympathetic denervation in long QT syndrome: Analysis of therapeutic nonresponders. Circ Arrhythm Electrophysiol 2013; 6: 705 –  711. 17. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: A distinct clinical and electrocardiographic syndrome: A multicenter report. J Am Coll Cardiol 1992; 20: 1391 – 1396. 18. Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with STsegment elevation. Circulation 1999; 100: 1660 – 1666. 19. Chen Q, Kirsch GE, Zhang D, Brugada R, Brugada J, Brugada P, et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 1998; 392: 293 – 296. 20. Antzelevitch C. Genetic, molecular and cellular mechanisms underlying the J wave syndromes. Circ J 2012; 76: 1054 – 1065. 21. Nakajima T, Wu J, Kaneko Y, Ashihara T, Ohno S, Irie T, et al. KCNE3 T4A as the genetic basis of Brugada-pattern electrocardiogram. Circ J 2012; 76: 2763 – 2772. 22. Cerrone M, Priori SG. Genetics of sudden death: Focus on inherited channelopathies. Eur Heart J 2011; 32: 2109 – 2118. 23. Belhassen B, Glick A, Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation 2004; 110: 1731 – 1737. 24. Aizawa Y, Yamakawa H, Takatsuki S, Katsumata Y, Nishiyama T, Kimura T, et al. Efficacy and safety of bepridil for prevention of ICD shocks in patients with Brugada syndrome and idiopathic ventricular fibrillation. Int J Cardiol 2013; 168: 5083 – 5085. 25. Shinohara T, Ebata Y, Ayabe R, Fukui A, Okada N, Yufu K, et al. Combination therapy of cilostazol and bepridil suppresses recurrent ventricular fibrillation related to J-wave syndromes. Heart Rhythm 2014; 11: 1441 – 1445. 26. Mahida S, Derval N, Sacher F, Berte B, Yamashita S, Hooks DA, et al. History and clinical significance of early repolarization syndrome. Heart Rhythm 2015; 12: 242 – 249. 27. Haissaguerre M, Derval N, Sacher F, Jesel L, Deisenhofer I, de Roy L, et al. Sudden cardiac arrest associated with early repolarization. N Engl J Med 2008; 358: 2016 – 2023. 28. Kaneko Y, Horie M, Niwano S, Kusano KF, Takatsuki S, Kurita T, et al. Electrical storm in patients with brugada syndrome is associated with early repolarization. Circ Arrhythm Electrophysiol 2014; 7: 1122 – 1128. 29. Haissaguerre M, Sacher F, Nogami A, Komiya N, Bernard A, Probst V, et al. Characteristics of recurrent ventricular fibrillation associated with inferolateral early repolarization role of drug therapy. J Am Coll Cardiol 2009; 53: 612 – 619. 30. Katsuumi G, Shimizu W, Watanabe H, Noda T, Nogami A, Ohkubo K, et al. Efficacy of bepridil to prevent ventricular fibrillation in severe form of early repolarization syndrome. Int J Cardiol 2014; 172: 519 – 522. 31. Leenhardt A, Lucet V, Denjoy I, Grau F, Ngoc DD, Coumel P. Cat-

1191 echolaminergic polymorphic ventricular tachycardia in children: A 7-year follow-up of 21 patients. Circulation 1995; 91: 1512 – 1519. 32. Leenhardt A, Denjoy I, Guicheney P. Catecholaminergic polymorphic ventricular tachycardia. Circ Arrhythm Electrophysiol 2012; 5: 1044 – 1052. 33. Kawamura M, Ohno S, Naiki N, Nagaoka I, Dochi K, Wang Q, et al. Genetic background of catecholaminergic polymorphic ventricular tachycardia in Japan. Circ J 2013; 77: 1705 – 1713. 34. Nyegaard M, Overgaard MT, Sondergaard MT, Vranas M, Behr ER, Hildebrandt LL, et al. Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death. Am J Hum Genet 2012; 91: 703 – 712. 35. Crotti L, Johnson CN, Graf E, De Ferrari GM, Cuneo BF, Ovadia M, et al. Calmodulin mutations associated with recurrent cardiac arrest in infants. Circulation 2013; 127: 1009 – 1017. 36. Nakajima T, Kaneko Y, Taniguchi Y, Hayashi K, Takizawa T, Suzuki T, et al. The mechanism of catecholaminergic polymorphic ventricular tachycardia may be triggered activity due to delayed afterdepolarization. Eur Heart J 1997; 18: 530 – 531. 37. Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE, et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med 2009; 15: 380 – 383. 38. Viskin S. Long QT syndromes and torsade de pointes. Lancet 1999; 354: 1625 – 1633. 39. Sesti F, Abbott GW, Wei J, Murray KT, Saksena S, Schwartz PJ, et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci USA 2000; 97: 10613 – 10618. 40. Yang P, Kanki H, Drolet B, Yang T, Wei J, Viswanathan PC, et al. Allelic variants in long-QT disease genes in patients with drugassociated torsades de pointes. Circulation 2002; 105: 1943 – 1948. 41. Lehtonen A, Fodstad H, Laitinen-Forsblom P, Toivonen L, Kontula K, Swan H. Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes. Heart Rhythm 2007; 4: 603 – 607. 42. Itoh H, Sakaguchi T, Ding WG, Watanabe E, Watanabe I, Nishio Y, et al. Latent genetic backgrounds and molecular pathogenesis in drug-induced long-QT syndrome. Circ Arrhythm Electrophysiol 2009; 2: 511 – 523. 43. Kaab S, Crawford DC, Sinner MF, Behr ER, Kannankeril PJ, Wilde AA, et al. A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes. Circ Cardiovasc Genet 2012; 5: 91 – 99. 44. Petersen CI, McFarland TR, Stepanovic SZ, Yang P, Reiner DJ, Hayashi K, et al. In vivo identification of genes that modify ether-ago-go-related gene activity in Caenorhabditis elegans may also affect human cardiac arrhythmia. Proc Natl Acad Sci USA 2004; 101: 11773 – 11778. 45. Nakajima T, Hayashi K, Viswanathan PC, Kim MY, Anghelescu M, Barksdale KA, et al. HERG is protected from pharmacological block by α-1,2-glucosyltransferase function. J Biol Chem 2007; 282: 5506 – 5513. 46. Hayashi K, Fujino N, Ino H, Uchiyama K, Sakata K, Konno T, et al. A KCR1 variant implicated in susceptibility to the long QT syndrome. J Mol Cell Cardiol 2011; 50: 50 – 57. 47. Jamshidi Y, Nolte IM, Dalageorgou C, Zheng D, Johnson T, Bastiaenen R, et al. Common variation in the NOS1AP gene is associated with drug-induced QT prolongation and ventricular arrhythmia. J Am Coll Cardiol 2012; 60: 841 – 850. 48. Postema PG, Wolpert C, Amin AS, Probst V, Borggrefe M, Roden DM, et al. Drugs and Brugada syndrome patients: Review of the literature, recommendations, and an up-to-date website (www. brugadadrugs.org). Heart Rhythm 2009; 6: 1335 – 1341. 49. Chevalier P, Bellocq C, Millat G, Piqueras E, Potet F, Schott JJ, et al. Torsades de pointes complicating atrioventricular block: Evidence for a genetic predisposition. Heart Rhythm 2007; 4: 170 – 174. 50. Subbiah RN, Gollob MH, Gula LJ, Davies RW, Leong-Sit P, Skanes AC, et al. Torsades de pointes during complete atrioventricular block: Genetic factors and electrocardiogram correlates. Can J Cardiol 2010; 26: 208 – 212. 51. Oka Y, Itoh H, Ding WG, Shimizu W, Makiyama T, Ohno S, et al. Atrioventricular block-induced Torsades de Pointes with clinical and molecular backgrounds similar to congenital long QT syndrome. Circ J 2010; 74: 2562 – 2571. 52. Numaguchi H, Mullins FM, Johnson JP Jr, Johns DC, Po SS, Yang IC, et al. Probing the interaction between inactivation gating and Dd-sotalol block of HERG. Circ Res 2000; 87: 1012 – 1018. 53. Yang T, Snyders DJ, Roden DM. Rapid inactivation determines the rectification and [K+]o dependence of the rapid component of the delayed rectifier K+ current in cardiac cells. Circ Res 1997; 80: 782 – 789.

Circulation Journal  Vol.79, June 2015

1192

NAKAJIMA T et al.

54. Guo J, Massaeli H, Xu J, Jia Z, Wigle JT, Mesaeli N, et al. Extracellular K+ concentration controls cell surface density of IKr in rabbit hearts and of the HERG channel in human cell lines. J Clin Invest 2009; 119: 2745 – 2757. 55. Etheridge SP, Compton SJ, Tristani-Firouzi M, Mason JW. A new oral therapy for long QT syndrome: Long-term oral potassium improves repolarization in patients with HERG mutations. J Am Coll Cardiol 2003; 42: 1777 – 1782. 56. Amin AS, Meregalli PG, Bardai A, Wilde AA, Tan HL. Fever increases the risk for cardiac arrest in the Brugada syndrome. Ann Intern Med 2008; 149: 216 – 218. 57. Samani K, Wu G, Ai T, Shuraih M, Mathuria NS, Li Z, et al. A novel SCN5A mutation V1340I in Brugada syndrome augmenting arrhythmias during febrile illness. Heart Rhythm 2009; 6: 1318 – 1326. 58. Keller DI, Huang H, Zhao J, Frank R, Suarez V, Delacretaz E, et al. A novel SCN5A mutation, F1344S, identified in a patient with Brugada syndrome and fever-induced ventricular fibrillation. Cardiovasc Res 2006; 70: 521 – 529. 59. Amin AS, Klemens CA, Verkerk AO, Meregalli PG, AsghariRoodsari A, de Bakker JM, et al. Fever-triggered ventricular arrhythmias in Brugada syndrome and type 2 long-QT syndrome. Neth Heart J 2010; 18: 165 – 169. 60. Amin AS, Herfst LJ, Delisle BP, Klemens CA, Rook MB, Bezzina CR, et al. Fever-induced QTc prolongation and ventricular arrhythmias in individuals with type 2 congenital long QT syndrome. J Clin Invest 2008; 118: 2552 – 2561. 61. Shibata R, Ashizawa N, Komiya N, Fukae S, Nakao K, Seto S, et al. Torsade de pointes triggered by high fever in patient with LQT2 syndrome. J Jpn Soc Intern Med 2009; 98: 1996 – 1998 (in Japanese). 62. Zhao JT, Hill AP, Varghese A, Cooper AA, Swan H, LaitinenForsblom PJ, et al. Not all hERG pore domain mutations have a severe phenotype: G584S has an inactivation gating defect with mild phenotype compared to G572S, which has a dominant negative trafficking defect and a severe phenotype. J Cardiovasc Electrophysiol 2009; 20: 923 – 930. 63. Tange T, Imai M, Ui G, Kogure S, Ono Y, Kobayashi N, et al. TdP developed in a fever opportunity, once had a diagnosis of druginduced LQT 7 years ago, showing KCNH2 mutant: A case report. Ther Res 2012; 33: 1639 – 1642 (in Japanese). 64. Smith PL, Baukrowitz T, Yellen G. The inward rectification mechanism of the HERG cardiac potassium channel. Nature 1996; 379: 833 – 836. 65. Nakajima T, Furukawa T, Tanaka T, Katayama Y, Nagai R, Nakamura Y, et al. Novel mechanism of HERG current suppression in LQT2: Shift in voltage dependence of HERG inactivation. Circ Res 1998; 83: 415 – 422. 66. Hu D, Viskin S, Oliva A, Carrier T, Cordeiro JM, Barajas-Martinez H, et al. Novel mutation in the SCN5A gene associated with arrhyth-

mic storm development during acute myocardial infarction. Heart Rhythm 2007; 4: 1072 – 1080. 67. Nakajima T, Davies SS, Matafonova E, Potet F, Amarnath V, Tallman KA, et al. Selective γ-ketoaldehyde scavengers protect NaV1.5 from oxidant-induced inactivation. J Mol Cell Cardiol 2010; 48: 352 – 359. 68. Halkin A, Roth A, Lurie I, Fish R, Belhassen B, Viskin S. Pausedependent torsade de pointes following acute myocardial infarction: A variant of the acquired long QT syndrome. J Am Coll Cardiol 2001; 38: 1168 – 1174. 69. Crotti L, Hu D, Barajas-Martinez H, De Ferrari GM, Oliva A, Insolia R, et al. Torsades de pointes following acute myocardial infarction: Evidence for a deadly link with a common genetic variant. Heart Rhythm 2012; 9: 1104 – 1112. 70. Nakajima T, Kaneko Y, Saito A, Irie T, Kato T, Iso T, et al. Post myocardial ischemia-associated torsades de pointes in a patient carrying a KCNQ1 G643S variant. Intern Med 2010; 49: 2587 – 2591. 71. Kubota T, Horie M, Takano M, Yoshida H, Takenaka K, Watanabe E, et al. Evidence for a single nucleotide polymorphism in the KCNQ1 potassium channel that underlies susceptibility to life-threatening arrhythmias. J Cardiovasc Electrophysiol 2001; 12: 1223 – 1229. 72. Ackerman MJ, Tester DJ, Jones GS, Will ML, Burrow CR, Curran ME. Ethnic differences in cardiac potassium channel variants: Implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome. Mayo Clin Proc 2003; 78: 1479 – 1487. 73. Jiang M, Cabo C, Yao J, Boyden PA, Tseng G. Delayed rectifier K currents have reduced amplitudes and altered kinetics in myocytes from infarcted canine ventricle. Cardiovasc Res 2000; 48: 34 – 43. 74. Yoshikawa T. Takotsubo cardiomyopathy, a new concept of cardiomyopathy: Clinical features and pathophysiology. Int J Cardiol 2014; 182: 297 – 303. 75. Madias C, Fitzgibbons TP, Alsheikh-Ali AA, Bouchard JL, Kalsmith B, Garlitski AC, et al. Acquired long QT syndrome from stress cardiomyopathy is associated with ventricular arrhythmias and torsades de pointes. Heart Rhythm 2011; 8: 555 – 561. 76. Grilo LS, Pruvot E, Grobety M, Castella V, Fellmann F, Abriel H. Takotsubo cardiomyopathy and congenital long QT syndrome in a patient with a novel duplication in the Per-Arnt-Sim (PAS) domain of hERG1. Heart Rhythm 2010; 7: 260 – 265. 77. Jeyaraj D, Ashwath M, Rosenbaum DS. Pathophysiology and clinical implications of cardiac memory. Pacing Clin Electrophysiol 2010; 33: 346 – 352. 78. Di Cori A, Zucchelli G, Romano S, Bongiorni MG. Proarrhythmic effect of pacing mode reprogramation in a patient with a congenital long-QT syndrome. J Cardiovasc Electrophysiol 2013; 24: 1304 –  1305.

Circulation Journal  Vol.79, June 2015

Unveiling specific triggers and precipitating factors for fatal cardiac events in inherited arrhythmia syndromes.

Patients with inherited arrhythmia syndromes, such as long QT syndrome, Brugada syndrome, early repolarization syndrome, catecholaminergic polymorphic...
610KB Sizes 0 Downloads 5 Views